MAPK1 and hepatocellular carcinoma: Further studies should elucidate the precise mechanism of HIGD2A activity in the modulation of the MAPK/ERK pathway, and explore the role of HIGD2A in HCC metastasis, and as a feasible to target for liver cancer therapy.